Talon CEO: Marqibo US FDA win provides hope for ‘hopeless’ Ph-ALL patients
This article was originally published in Scrip
After winning over two of the most skeptical members of the US FDA's Oncologic Drugs Advisory Committee (ODAC) at a 21 March meeting – panel chairman Dr Wyndham Wilson, chief of lymphoma therapeutics in the Metabolism Branch at the US National Cancer Institute (NCI) and Dr Mikkael Sekeres, an associate professor of medicine at the Cleveland Clinic in Ohio – it perhaps should have come as no surprise that Talon Therapeutics gained the agency's OK on 9 August for Marqibo (vincristine sulfate liposomes injection).
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.